Medicine 2.0's reliance on actuarial life expectancy data for older individuals can lead to under-treatment of slow-moving cancers, potentially prioritizing lifespan over healthspan.

“Well, I think one reason comes down to again the failure of medicine 2.0, which tends to rely on actuarial data of life expectancy. That's it. And it says, look, if you're 72y old man, which is apparently the age at which um President Biden was last tested, it says, look, your life expectancy is x number of years. It's less than 15 actuarially. Um and this is, you know, a relatively slowmoving cancer all things considered. So, we should do nothing about it. But yet here we are. It's 11 years later and he has a very aggressive form of prostate cancer. And so two things turned out to be incorrect. One, we didn't actually know what his life expectancy was. But more importantly, we placed an emphasis on lifespan over health span.”